Abstract 99P
Background
The KCSG AL20-17/KM23 trial assessed the efficacy of neratinib combined with trastuzumab in heavily pretreated patients with HER2-mutated solid tumors. This study aimed to investigate the potential of circulating tumor DNA (ctDNA) as a biomarker for predicting treatment outcomes with this dual anti-HER2 combination.
Methods
ctDNA samples were collected during the screening visit before treatment initiation and either at the end of treatment or upon disease progression. This report primarily focuses on analyzing the screening samples using Guardant360® to identify pathogenic mutations based on the ClinVar or OncoKB databases.
Results
Among the 40 enrolled patients, ctDNA from 32 individuals was successfully analyzed. Most patients exhibited HER2 mutations in their ctDNA consistent with those found in their tumor tissues. However, three patients showed no detectable HER2 mutations in their ctDNA, of whom two had stable disease, and one had progressive disease as their best response. Other prevalent mutations included TP53 mutations (n=20), EGFR amplification (n=6), PIK3CA amplification (n=3), HER2 amplification (n=3), and KRAS mutation (n=3). EGFR amplification tended to be associated with shorter survival, although not statistically significant (median PFS 2.02 vs 3.42 months, p = 0.055; median OS 5.98 vs 13.71 months, p = 0.153). The median ctDNA fraction was 5.705% (range: 0.11-71.97). Higher ctDNA fractions were associated with poorer survival outcomes, with a selected cutoff point of 11.47% (median PFS 4.87 vs 2.01 months, p = 0.02; median OS 13.71 vs 4.64 months, p = 0.036).
Conclusions
This study underscores the potential of ctDNA as a predictive and prognostic biomarker for patients with HER2-mutated advanced-stage solid tumors treated with neratinib and trastuzumab. The presence of HER2 mutations in ctDNA generally matched those in tumor tissues, and elevated ctDNA fractions were linked to poorer outcomes. Further research is necessary to validate the role of ctDNA in optimizing anti-HER2 therapy for HER2-mutated tumors.
Clinical trial identification
NCT06083662.
Editorial acknowledgement
Legal entity responsible for the study
Korean Cancer Study Group (KCSG).
Funding
Korean Cancer Study Group (KCSG); Ministry of Health & Welfare, Republic of Korea (grant number: HI17C2206).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
93P - UriMee: A novel non-invasive test for diagnosis of urothelial carcinoma by detection of methylation markers in urinary sediment DNA
Presenter: Ming cao
Session: Poster session 07
94P - A one-tube multiplex methylation-specific droplet digital PCR assay for identification of ctDNA biomarkers in anal squamous cell carcinoma
Presenter: Karen-Lise Spindler
Session: Poster session 07
95P - Baseline-informed longitudinal monitoring of lung cancer by cell-free DNA methylation profiles
Presenter: Chunxia Su
Session: Poster session 07
96P - A novel strategy for single-nucleus RNA-seq of frozen PAXgene blood: A clinical alternative to single-cell RNA-seq of cryopreserved PBMCs
Presenter: Asaf Rotem
Session: Poster session 07
97P - GENIE-seq: A novel methylation sequencing method for effective and accurate identification of methylation markers from cfDNA
Presenter: Zhaoyun Ding
Session: Poster session 07
98P - Translating cancer tissue methylation to cell-free DNA methylation for minimally invasive cancer detection
Presenter: Edward Post
Session: Poster session 07
100P - Predicting tumor ER and HER2 status using a cell-free RNA liquid biopsy assay
Presenter: Lee Schwartzberg
Session: Poster session 07
101P - Circulating tumor DNA minimal residual disease predicts the risk of progression after long-term response to first-line immunotherapy in advanced NSCLC
Presenter: Fang Wu
Session: Poster session 07